The special immunotherapy edition of Perspective magazine is live

Blue Latitude Health|19th May 2016

As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.

In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.

 

The immunotherapy special issue covers:

  • Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
  • Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
  • What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
  • The immuno-therapy patient experience as a customer journey.

 

Click the button below to enter your details and receive your digital copy.

What everyone forgets about good organisational change in pharma

Natasha Cowan, Daphne Chung|11th October 2018

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account.

read more

The outlook for oncology marketing

Fred Bassett, David Cooney|2nd October 2018

Co-founder and Head of Strategy Fred Bassett and Senior Consultant David Cooney give their expert views in the latest MM&M 'Oncology Marketing Perspectives' eBook. Dowload it now to find out what's next for the cancer sector. 

read more

The dark side of direct-to-consumer genetic tests

Natasha Cowan|28th September 2018

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients to unnecessary surgeries, we reveal the barriers for healthcare professionals and patients, and how to solve these industry challenges.

read more